Iranian Red Crescent Medical Journal

Published by: Kowsar

The Effect of a Single Intramuscular Injection of Cholecalciferol on the Serum Levels of Vitamin D, Adiponectin, Insulin Resistance, and Liver Function in Women with Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized, Controlled Clinical Trial

Sonia Mansourian Hosseini 1 , Soodabeh Aliashrafi 1 and Mehrangiz Ebrahimi-Mameghani 2 , *
Authors Information
1 Student Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
2 Nutrition Research Center, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • Iranian Red Crescent Medical Journal: October 2018, 20 (10); e60746
  • Published Online: September 18, 2018
  • Article Type: Research Article
  • Received: August 22, 2017
  • Revised: December 1, 2017
  • Accepted: February 14, 2018
  • DOI: 10.5812/ircmj.60746

To Cite: Mansourian Hosseini S, Aliashrafi S, Ebrahimi-Mameghani M. The Effect of a Single Intramuscular Injection of Cholecalciferol on the Serum Levels of Vitamin D, Adiponectin, Insulin Resistance, and Liver Function in Women with Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized, Controlled Clinical Trial, Iran Red Crescent Med J. 2018 ; 20(10):e60746. doi: 10.5812/ircmj.60746.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Foroughi M, Maghsoudi Z, Ghiasvand R, Iraj B, Askari G. Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. Int J Prev Med. 2014;5(8):969-75. [PubMed: 25489444]. [PubMed Central: PMC4258669].
  • 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30. doi: 10.1210/jc.2011-0385. [PubMed: 21646368].
  • 3. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153-8. doi: 10.1210/jc.2011-2601. [PubMed: 22442274].
  • 4. Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol. 2014;144 Pt A:5-11. doi: 10.1016/j.jsbmb.2013.11.004. [PubMed: 24239506]. [PubMed Central: PMC4144817].
  • 5. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J. 2013;60(6):743-52. doi: 10.1507/endocrj.EJ12-0387. [PubMed: 23411507].
  • 6. Musso G. Non-alcoholic fatty liver, adipose tissue, and the bone: A new triumvirate on the block. Endocrine. 2012;42(2):237-9. doi: 10.1007/s12020-012-9748-2. [PubMed: 22801991].
  • 7. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85. doi: 10.1186/1741-7015-9-85. [PubMed: 21749681]. [PubMed Central: PMC3148980].
  • 8. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int J Clin Exp Med. 2015;8(10):17221-34. [PubMed: 26770315]. [PubMed Central: PMC4694215].
  • 9. Hashemi Kani A, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Dietary quality indices and biochemical parameters among patients with non alcoholic fatty liver disease (NAFLD). Hepat Mon. 2013;13(7). e10943. doi: 10.5812/hepatmon.10943. [PubMed: 24065998]. [PubMed Central: PMC3776150].
  • 10. Kocot J, Dziemidok P, Kielczykowska M, Kurzepa J, Szczesniak G, Musik I. Is there any relationship between plasma 25-Hydroxyvitamin D(3), adipokine profiles and excessive body weight in type 2 diabetic patients? Int J Environ Res Public Health. 2017;15(1). doi: 10.3390/ijerph15010019. [PubMed: 29295491]. [PubMed Central: PMC5800119].
  • 11. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: Multiple interactions. Int J Mol Sci. 2017;18(8). doi: 10.3390/ijms18081649. [PubMed: 28758929]. [PubMed Central: PMC5578039].
  • 12. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol. 2009;160(6):965-71. doi: 10.1530/EJE-08-0952. [PubMed: 19289535].
  • 13. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012;8(3). e1002607. doi: 10.1371/journal.pgen.1002607. [PubMed: 22479202]. [PubMed Central: PMC3315470].
  • 14. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91-100. doi: 10.1172/JCI17797. [PubMed: 12840063]. [PubMed Central: PMC162288].
  • 15. Neyestani TR, Nikooyeh B, Alavi-Majd H, Shariatzadeh N, Kalayi A, Tayebinejad N, et al. Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(6):2005-11. doi: 10.1210/jc.2011-3465. [PubMed: 22442277].
  • 16. Baziar N, Jafarian K, Shadman Z, Qorbani M, Khoshniat Nikoo M, Abd Mishani M. Effect of therapeutic dose of vitamin d on serum adiponectin and glycemia in vitamin d-insufficient or deficient type 2 diabetic patients. Iran Red Crescent Med J. 2014;16(9). e21458. doi: 10.5812/ircmj.21458. [PubMed: 25593737]. [PubMed Central: PMC4270651].
  • 17. Belenchia AM, Tosh AK, Hillman LS, Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: A randomized controlled trial. Am J Clin Nutr. 2013;97(4):774-81. doi: 10.3945/ajcn.112.050013. [PubMed: 23407306].
  • 18. Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(26):8341-50. doi: 10.3748/wjg.v20.i26.8341. [PubMed: 25024593]. [PubMed Central: PMC4093688].
  • 19. Ostad Rahimi AR, Mahbob SA, Abbas Alizadeh Farhanghi M, Vahed Jabarii M. [The effect of cholecalciferol injection on serum 25 hydroxy vitamin D and parathyroid hormone in obese and none obese reproductive age women]. Pharm Sci. 2009;15(1):9-16. Persian.
  • 20. Khan AH, Rohra DK, Saghir SA, Udani SK, Wood R, Jabbar A. Response of a single 'mega intramuscular dose' of vitamin D on serum 25OHD and parathyroid hormone levels. J Coll Physicians Surg Pak. 2012;22(4):207-12. [PubMed: 22482374].
  • 21. Aadahl M, Jorgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003;35(7):1196-202. doi: 10.1249/01.MSS.0000074446.02192.14. [PubMed: 12840642].
  • 22. Einarsdottir K, Preen DB, Clay TD, Kiely L, Holman CD, Cohen LD. Effect of a single 'megadose' intramuscular vitamin D (600,000 IU) injection on vitamin D concentrations and bone mineral density following biliopancreatic diversion surgery. Obes Surg. 2010;20(6):732-7. doi: 10.1007/s11695-009-0024-3. [PubMed: 19949888].
  • 23. Cipriani C, Romagnoli E, Pepe J, Russo S, Carlucci L, Piemonte S, et al. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: Implications for treatment and prophylaxis. J Clin Endocrinol Metab. 2013;98(7):2709-15. doi: 10.1210/jc.2013-1586. [PubMed: 23766519].
  • 24. Heshmat R, Tabatabaei-Malazy O, Abbaszadeh-Ahranjani S, Shahbazi S, Khooshehchin G, Bandarian F, et al. Effect of vitamin D on insulin resistance and anthropometric parameters in type 2 diabetes; a randomized double-blind clinical trial. Daru. 2012;20(1):10. doi: 10.1186/2008-2231-20-10. [PubMed: 23351271]. [PubMed Central: PMC3555787].
  • 25. Manco M. Insulin resistance and NAFLD: A dangerous liaison beyond the Genetics. Children (Basel). 2017;4(8). doi: 10.3390/children4080074. [PubMed: 28805745]. [PubMed Central: PMC5575596].
  • 26. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol. 2011;55(2):415-25. doi: 10.1016/j.jhep.2010.11.028. [PubMed: 21184788].
  • 27. Mozaffari-Khosravi H, Hosseinzadeh-Shamsi-Anar M, Salami MA, Hadinedoushan H, Mozayan MR. Effects of a single post-partum injection of a high dose of vitamin D on glucose tolerance and insulin resistance in mothers with first-time gestational diabetes mellitus. Diabet Med. 2012;29(1):36-42. doi: 10.1111/j.1464-5491.2011.03473.x. [PubMed: 21977923].
  • 28. Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47(1):70-80. doi: 10.1007/s12020-014-0336-5. [PubMed: 24968737].
  • 29. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4):549-55. doi: 10.1017/S0007114509992017. [PubMed: 19781131].
  • 30. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17(11):863-9. doi: 10.1016/j.annepidem.2007.05.013. [PubMed: 17728149].
  • 31. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117(9):2621-37. doi: 10.1172/JCI31021. [PubMed: 17717599]. [PubMed Central: PMC1950456].
  • 32. Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119(10):431-6. doi: 10.1042/CS20100008. [PubMed: 20524936]. [PubMed Central: PMC2916712].
  • 33. Lee S, Lee DK, Choi E, Lee JW. Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol Endocrinol. 2005;19(2):399-408. doi: 10.1210/me.2004-0324. [PubMed: 15528275].
  • 34. Skaaby T, Husemoen LL, Borglykke A, Jorgensen T, Thuesen BH, Pisinger C, et al. Vitamin D status, liver enzymes, and incident liver disease and mortality: A general population study. Endocrine. 2014;47(1):213-20. doi: 10.1007/s12020-013-0107-8. [PubMed: 24272594].
  • 35. Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92. doi: 10.1186/s12916-016-0638-y. [PubMed: 27353492]. [PubMed Central: PMC4926287].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments